Compare ADEA & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADEA | PBLS |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 2020 | 2026 |
| Metric | ADEA | PBLS |
|---|---|---|
| Price | $27.81 | $35.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $31.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 405.2K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $443,386,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.63 | N/A |
| P/E Ratio | $81.03 | ★ N/A |
| Revenue Growth | ★ 17.91 | N/A |
| 52 Week Low | $11.61 | $25.56 |
| 52 Week High | $34.34 | $36.82 |
| Indicator | ADEA | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 66.14 |
| Support Level | $26.57 | $26.42 |
| Resistance Level | $34.02 | N/A |
| Average True Range (ATR) | 2.02 | 2.44 |
| MACD | 0.38 | 0.32 |
| Stochastic Oscillator | 52.77 | 86.81 |
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.